Metabolic tumor volume and sites of organ involvement predict outcome in NSCLC immune-checkpoint inhibitor therapy

The purpose of this study was to assess the ability of pretreatment PET parameters and peripheral blood biomarkers to predict progression-free survival (PFS) and overall survival (OS) in NSCLC patients treated with ICIT. We prospectively included 87 patients in this study who underwent pre-treatment...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	European journal of radiology 2024-01, Vol.170, p.111198-111198, Article 111198
Hauptverfasser:	Kifjak, Daria, Hochmair, Maximilian, Sobotka, Daniel, Haug, Alexander R., Ambros, Raphael, Prayer, Florian, Heidinger, Benedikt H., Roehrich, Sebastian, Milos, Ruxandra-Iulia, Wadsak, Wolfgang, Fuereder, Thorsten, Krenbek, Dagmar, Fazekas, Andreas, Meilinger, Michael, Mayerhoefer, Marius E., Langs, Georg, Herold, Christian, Prosch, Helmut, Beer, Lucian
Format:	Artikel
Sprache:	eng
Schlagworte:	Carcinoma, Non-Small-Cell Lung - diagnostic imaging Carcinoma, Non-Small-Cell Lung - drug therapy Fluorodeoxyglucose F18 - metabolism Glycolysis Humans Immune Checkpoint Inhibitors Immune-checkpoint inhibitor Lung Neoplasms - diagnostic imaging Lung Neoplasms - drug therapy Lung Neoplasms - metabolism Metabolic tumor volume NSCL Outcome PET Positron Emission Tomography Computed Tomography Prognosis Radiopharmaceuticals Retrospective Studies Survival Tumor Burden
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!